QY201, a novel oral dual Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) inhibitor, demonstrated robust efficacy in adults with moderate-to-severe atopic dermatitis (AD).
The phase 2 randomized, double-blind, placebo-controlled trial showed significant improvement with QY201 at doses of 5 mg, 10 mg, and 20 mg twice daily compared with placebo, particularly in EASI-75 response rates.
Safety profile was favorable overall, with mostly mild to moderate treatment-emergent adverse events comparable to placebo, supporting dose selection for phase 3 studies.
Study limitations include relatively short 12-week follow-up and enrollment limited to a single country, warranting further global investigation.
